The DOI matches its Crossref record; 236 of the 236 references it cites were found in a registry or an index.
Mechanisms of Resistance to Endocrine Therapy in Breast Cancer: Focus on Signaling Pathways, miRNAs and Genetically Based Resistance
Open accessAbstract
Breast cancer is the most frequent malignancy diagnosed in women. Approximately 70% of breast tumors express the estrogen receptor (ER). Tamoxifen and aromatase inhibitors (AIs) are the most common and effective therapies for patients with ERα-positive breast cancer. Alone or combined with chemotherapy, tamoxifen significantly reduces disease progression and is associated with more favorable impact on survival in patients. Unfortunately, endocrine resistance occurs, either de novo or acquired during the course of the treatment. The mechanisms that contribute to hormonal resistance include loss or modification in the ERα expression, regulation of signal transduction pathways, altered expression of specific microRNAs, balance of co-regulatory proteins, and genetic polymorphisms involved in tamoxifen metabolic activity. Because of the clinical consequences of endocrine resistance, new treatment strategies are arising to make the cells sensitive to tamoxifen. Here, we will review the current knowledge on mechanisms of endocrine resistance in breast cancer cells. In addition, we will discuss novel therapeutic strategies to overcome such resistance. Undoubtedly, circumventing endocrine resistance should help to improve therapy for the benefit of breast cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Items 201–236 of 236
Regulation of estrogen receptor-alpha expression by the tumor suppressor gene p53 in MCF-7 cells
Angeloni, S., Martin, M., García-Morales, P., Castro-Galache, M. D., Ferragut, J. A., & Saceda, M. (2004) · Journal of Endocrinology · doi:10.1677/joe.0.1800497 · Cited by 73
McBryan, J., Theissen, S. M., Byrne, C., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-2073 · Cited by 73
Borgquist, S., Holm, C., Stendahl, M., Anagnostaki, L., Landberg, G., & Jirström, K. (2008) · Journal of Clinical Pathology · doi:10.1136/jcp.2006.040378 · Cited by 73
MicroRNAs as therapeutic targets and their potential applications in cancer therapy
Cho, W. C. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.696102 · Cited by 70
Santen, R. J., Song, R. X.-D., Masamura, S., et al. (2008) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-78818-0_2 · Cited by 67
Gradishar, W. J. (2004) · The Oncologist · doi:10.1634/theoncologist.9-4-378 · Cited by 67
Advances in Adjuvant Hormonal Therapy for Postmenopausal Women
Strasser‐Weippl, K., & Goss, P. E. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.038 · Cited by 66
The Role of Amphiregulin in Exemestane-Resistant Breast Cancer Cells: Evidence of an Autocrine Loop
Wang, X., Masri, S., Phung, S., & Chen, S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5544 · Cited by 64
Growth factor signalling in endocrine and anti-growth factor resistant breast cancer
Nicholson, R. I., Hutcheson, I. R., Jones, H. E., Hiscox, S., Giles, M. G., Taylor, K. M., & Gee, J. M. W. (2007) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-007-9033-5 · Cited by 62
McCartan, D. P., Bolger, J. C., Fagan, A., Byrne, C., Yuan, H., Qin, L., McIlroy, M., Xu, J., Hill, A. D. K., Gaora, P. Ó., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1976 · Cited by 62
Lyng, M., Lænkholm, A., Søkilde, R., Thomsen, K. G., Litman, T., & Ditzel, H. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036170 · Cited by 61
Epigenetic Regulation in Estrogen Receptor Positive Breast Cancer—Role in Treatment Response
Pathiraja, T. N., Stearns, V., & Oesterreich, S. (2010) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-010-9166-0 · Cited by 58
Steroid receptor and microRNA regulation in cancer
Tessel, M. A., Krett, N. L., & Rosen, S. T. (2010) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32833ea80c · Cited by 57
Germline pharmacogenomics in oncology: Decoding the patient for targeting therapy
O’Donnell, P. H., & Ratain, M. J. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.01.005 · Cited by 50
Miyoshi, Y., Taguchi, T., Kim, S. J., Tamaki, Y., & Noguchi, S. (2005) · Breast Cancer · doi:10.2325/jbcs.12.11 · Cited by 50
Minireview: Steroid Receptor Coactivator-3: A Multifarious Coregulator in Mammary Gland Metastasis
Lydon, J. P., & O’Malley, B. W. (2010) · Endocrinology · doi:10.1210/en.2010-1012 · Cited by 49
Weigel, M. T., Ghazoui, Z. F., Dunbier, A. K., Pancholi, S., Dowsett, M., & Martin, L. (2012) · Breast Cancer Research · doi:10.1186/bcr3191 · Cited by 48
Buck, M. B., Pfizenmaier, K., & Knabbe, C. (2004) · Molecular Endocrinology · doi:10.1210/me.2003-0278 · Cited by 47
Coxon, A., Bush, T. L., Saffran, D. C., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1155 · Cited by 45
Hormonal therapy for postmenopausal breast cancer: the science of sequencing
Miller, W. R., Bartlett, J. M. S., Canney, P. A., & Verrill, M. W. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9369-7 · Cited by 44
Flågeng, M. H., Moi, L. L. H., Dixon, J. M., Geisler, J., Lien, E. A., Miller, W. R., Lønning, P. E., & Mellgren, G. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605324 · Cited by 43
Correction: Estrogen Modulates Notch Activity
(2008) · Cancer Research · doi:10.1158/0008-5472.can-68-17-cor1 · Cited by 43
Chen, A. C., Migliaccio, I., Rimawi, M. F., López‐Tarruella, S., Creighton, C. J., Massarweh, S. A., Huang, C., Wang, Y.-C., Batra, S. K., Gutierrez, M. C., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2082-9 · Cited by 41
Brodie, A., & Sabnis, G. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2920 · Cited by 34
Cutrupi, S., Reineri, S., Panetto, A., Grosso, E., Caizzi, L., Ricci, L., Friard, O., Agati, S., Scatolini, M., Chiorino, G., et al. (2012) · Oncogene · doi:10.1038/onc.2011.627 · Cited by 30
Emde, A., Mahlknecht, G., Maslak, K., Ribba, B., Sela, M., Possinger, K., & Yarden, Y. (2011) · Translational Oncology · doi:10.1593/tlo.11127 · Cited by 30
Sikora, M. J., Strumba, V., Lippman, M. E., Johnson, M. D., & Rae, J. M. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2032-6 · Cited by 30
Multiple mechanisms of estrogen receptor gene repression contribute to ER-negative breast cancer
Parl, F. F. (2003) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500201 · Cited by 28
Kressler, D., Hock, M. B., & Kralli, A. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m705596200 · Cited by 26
Moi, L. L. H., Flågeng, M. H., Gandini, S., Guerrieri‐Gonzaga, A., Bonanni, B., Lazzeroni, M., Gjerde, J., Lien, E. A., DeCensi, A., & Mellgren, G. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1859 · Cited by 26
Regulation of estrogen receptor-alpha expression in MCF-7 cells by taxol
Martin, M., Angeloni, S., García-Morales, P., Sholler, P. F., Castro-Galache, M. D., Ferragut, J. A., & Saceda, M. (2004) · Journal of Endocrinology · doi:10.1677/joe.0.1800487 · Cited by 24
Cottone, E., Orso, F., Biglia, N., Sismondi, P., & Bortoli, M. D. (2001) · The International Journal of Biological Markers · doi:10.1177/172460080101600301 · Cited by 24
Toward Individualized Breast Cancer Therapy: Translating Biological Concepts to the Bedside
Hortobágyi, G. N. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0032 · Cited by 23
An Overview of Letrozole in Postmenopausal Women with Hormone-Responsive Breast Cancer
Barnadas, A., García‐Estévez, L., Lluch-Hernández, A., Rodríguez-Lescure, Á., Rodriguez-Sanchez, C., & Sánchez‐Rovira, P. (2011) · Advances in Therapy · doi:10.1007/s12325-011-0075-4 · Cited by 22
CDK10 is not a target for aberrant DNA methylation in breast cancer.
Heller, G., Ziegler, B., Brandstetter, A., Novak, S., Rudas, M., Hennig, G., Gehrmann, M. C., Acht, T., Zöchbauer‐Müller, S., & Filipits, M. (2009) · Anticancer Research · Cited by 16
Tengström, M., Mannermaa, A., Kosma, V., Hirvonen, A., & Kataja, V. V. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-257 · Cited by 15
Cited by
PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects
Miricescu, D., Totan, A., Stanescu-Spinu, I.-I., Badoiu, S. C., Stefani, C., & Greabu, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010173 · Cited by 845
Jeselsohn, R., Yelensky, R., Buchwalter, G., Frampton, G., Meric-Bernstam, F., Gonzalez-Angulo, A. M., Ferrer-Lozano, J., Perez-Fidalgo, J. A., Cristofanilli, M., Gómez, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2332 · Cited by 674
Piccart, M., Hortobagyi, G. N., Campone, M., Pritchard, K. I., Lebrun, F., Ito, Y., Noguchi, S., Perez, A., Rugo, H. S., Deleu, I., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu456 · Cited by 574
Patel, H. K., & Bihani, T. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.12.012 · Cited by 499
Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis
Reiter, R., Rosales-Corral, S., Tan, D.-X., Acuna-Castroviejo, D., Qin, L., Yang, S.-F., & Xu, K. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040843 · Cited by 433
Metadata
- Authors
- García-Becerra, R., Santos, N., Díaz, L., & Camacho, J.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2012-12-20
- Volume
- 14
- Issue
- 1
- Pages
- 108-145
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2052631876
- Cited by
- 253
- References
- 236
- FWCI
- 7.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.